The ethnomedicinal and functional uses, phytochemical and pharmacology of compounds from Ardisia species: An updated review

IF 10.9 1区 医学 Q1 CHEMISTRY, MEDICINAL Medicinal Research Reviews Pub Date : 2022-06-06 DOI:10.1002/med.21894
Bingrui Liu, Rongyu Liu, Qifeng Liu, Charles R. Ashby Jr., Hang Zhang, Zhe-Sheng Chen
{"title":"The ethnomedicinal and functional uses, phytochemical and pharmacology of compounds from Ardisia species: An updated review","authors":"Bingrui Liu,&nbsp;Rongyu Liu,&nbsp;Qifeng Liu,&nbsp;Charles R. Ashby Jr.,&nbsp;Hang Zhang,&nbsp;Zhe-Sheng Chen","doi":"10.1002/med.21894","DOIUrl":null,"url":null,"abstract":"<p>Medicinal plants are considered to be a critical source of novel compounds and pharmacophores. The genus <i>Ardisia</i>, consisting of approximately 500 species, is the largest genus in the Myrsinaceae family. <i>Ardisia</i> species are widely distributed throughout tropical and subtropical regions of the world and have been used for the treatment of cancer, hypertension, irregular menstruation, gonorrhea, diarrhea and postnatal syndromes, among others. Phytochemical studies of <i>Ardisia</i> species have resulted in the isolation and identification of 111 compounds, including triterpenoid saponins, quinones, phenols, coumarins, cyclic depsipepetide and flavonoids. Crude extracts and isolates from <i>Ardisia</i> have been reported to have in vitro and in vivo efficacies, including but not limited to anticancer, antiinflammatory, antimicrobial, antioxidant, antithrombotic and antidiabetic, antitubercular compounds. This review focuses on the medical and functional uses, phytochemical profile and pharmacological efficacies of <i>Ardisia</i> species over the past 15 years. This review will provide information indicating that <i>Ardisia</i> species represent an invaluable source of potential therapeutic compounds.</p>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"42 5","pages":"1888-1929"},"PeriodicalIF":10.9000,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/med.21894","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Medicinal plants are considered to be a critical source of novel compounds and pharmacophores. The genus Ardisia, consisting of approximately 500 species, is the largest genus in the Myrsinaceae family. Ardisia species are widely distributed throughout tropical and subtropical regions of the world and have been used for the treatment of cancer, hypertension, irregular menstruation, gonorrhea, diarrhea and postnatal syndromes, among others. Phytochemical studies of Ardisia species have resulted in the isolation and identification of 111 compounds, including triterpenoid saponins, quinones, phenols, coumarins, cyclic depsipepetide and flavonoids. Crude extracts and isolates from Ardisia have been reported to have in vitro and in vivo efficacies, including but not limited to anticancer, antiinflammatory, antimicrobial, antioxidant, antithrombotic and antidiabetic, antitubercular compounds. This review focuses on the medical and functional uses, phytochemical profile and pharmacological efficacies of Ardisia species over the past 15 years. This review will provide information indicating that Ardisia species represent an invaluable source of potential therapeutic compounds.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
紫荆属植物化合物的民族医药和功能用途、植物化学和药理研究进展
药用植物被认为是新化合物和药效团的重要来源。紫金花属大约有500种,是紫金花科中最大的属。紫荆属植物广泛分布于世界热带和亚热带地区,被用于治疗癌症、高血压、月经不调、淋病、腹泻和产后综合症等。通过植物化学研究,分离鉴定了111个化合物,包括三萜皂苷、醌类、酚类、香豆素、环去肽和类黄酮。据报道,紫荆属植物的粗提取物和分离物具有体外和体内功效,包括但不限于抗癌、抗炎、抗菌、抗氧化、抗血栓和抗糖尿病、抗结核化合物。本文综述了近15年来紫荆属植物的药用和功能用途、植物化学特征和药理作用。本综述将提供的信息表明,紫荆属植物是潜在治疗化合物的宝贵来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
29.30
自引率
0.00%
发文量
52
审稿时长
2 months
期刊介绍: Medicinal Research Reviews is dedicated to publishing timely and critical reviews, as well as opinion-based articles, covering a broad spectrum of topics related to medicinal research. These contributions are authored by individuals who have made significant advancements in the field. Encompassing a wide range of subjects, suitable topics include, but are not limited to, the underlying pathophysiology of crucial diseases and disease vectors, therapeutic approaches for diverse medical conditions, properties of molecular targets for therapeutic agents, innovative methodologies facilitating therapy discovery, genomics and proteomics, structure-activity correlations of drug series, development of new imaging and diagnostic tools, drug metabolism, drug delivery, and comprehensive examinations of the chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of significant drugs.
期刊最新文献
Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities. Issue Information Front Cover Image, Volume 44, Issue 6 Inside Front Cover Image, Volume 44, Issue 6 An overview of the progress made in research into the Mpox virus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1